Madison Asset Management LLC Grows Holdings in Amgen Inc. $AMGN

Posted by Stanley Muller on Jul 22nd, 2026

Madison Asset Management LLC grew its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 17.9% in the first quarter, HoldingsChannel reports. The fund owned 11,552 shares of the medical research company’s stock after acquiring an additional 1,755 shares during the quarter. Madison Asset Management LLC’s holdings in Amgen were worth $4,065,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Norges Bank purchased a new position in shares of Amgen in the 4th quarter valued at about $2,164,162,000. Capital World Investors boosted its position in Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares in the last quarter. State Street Corp boosted its position in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares in the last quarter. Geode Capital Management LLC grew its holdings in Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after purchasing an additional 1,035,779 shares during the period. Finally, Amundi grew its holdings in Amgen by 41.1% in the fourth quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock valued at $1,111,854,000 after purchasing an additional 988,856 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on AMGN shares. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Morgan Stanley dropped their price target on shares of Amgen from $340.00 to $333.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 8th. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 price target on shares of Amgen in a report on Monday, July 6th. Argus reduced their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Finally, Guggenheim increased their price objective on shares of Amgen from $340.00 to $343.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $356.62.

Read Our Latest Stock Report on AMGN

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $366.24 on Wednesday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $391.29. The firm has a market capitalization of $197.66 billion, a PE ratio of 25.49, a P/E/G ratio of 3.68 and a beta of 0.41. The business’s 50 day moving average price is $348.98 and its 200-day moving average price is $351.05.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts expect that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Madison Asset Management LLC Grows Holdings in Amgen Inc. $AMGN

Insider Activity

Analysts Set New Price Targets

Amgen Stock Performance

About Amgen

Further Reading

You might be interested in: